Bullish Case: Both Helium and market densities peak near $95 (spot $94.295), with October IV at ~28% market vs ~23% Helium — event risk already priced and compressible. Q2 delivered a beat, raised EPS guidance ($8.47–$8.59), hip-share gains and >50% domestic ROSA expansion; the stock is only +4.4% over 90 days and -37% vs five-year levels, leaving mean-reversion room. Calls out-traded puts 62% this week, and the term structure is flat, favoring grind-higher drift toward $100.

Bearish Case: Helium's own price forecast is -2.65% and ZBH just fell 4.2% in a week on flat tape with options volume at the 0th percentile — interest is evaporating, not building. The Helium-minus-market uncertainty surface shows Helium IV ~2% above market, meaning premium is arguably rich, not cheap. Price-to-book 2.1 offers limited valuation cushion, and Precision Orthopedics litigation plus China/price-erosion pressures keep downside tails ($85–$90 carries real density mass) live into October.

Potential Outcomes:

1. ~40% Range/mean reversion: $92–$99 grind; flat IV curve compresses, falsifiable if spot holds above $94 with falling October IV.
2. ~25% Constructive drift: $97–$103 on ROSA adoption data or peer read-throughs; falsifiable via call skew flattening while spot rises.
3. ~20% Downside slip: $86–$92 on litigation headlines, EM/China softness or weak pre-announcement; falsifiable via widening put IV.
4. ~10% Macro/risk-off: SPY IV rising drags ZBH -8% to -12%.
5. ~5% Upside breakout: >$103 on M&A or guidance pre-announcement.

Trading Oracle: Sign Up to access trading oracle trade ideas.

September 22, 2026